Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Results from the TELLOMAK phase 2 trial.

被引：0

作者：

Porcu, Pierluigi

Bagot, Martine

Ram-Wolff, Caroline

Kim, Youn H.

Huen, Auris

Dalle, Stephane

Poligone, Brian

Mehta-Shah, Neha

Modeste, Anne Benedicte Duval

Zinzani, Pier Luigi

Woei-A-Jin, Feng Jung Sherida Harriette

Eigentler, Thomas

Combalia, Andrea

Sokol, Lubomir

Battistella, Maxime

Gru, Alejandro

Teisserenc, Helene Moins

Viotti, Julien

Paiva, Christine

Chammard, Agnes Boyer

机构：

[1] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA USA

[2] Univ Paris Cite, Hop St Louis, INSERM, U976, Paris, France

[3] Stanford Univ, Dept Dermatol, Multidisciplinary Cutaneous Lymphoma Program, Stanford, CA USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX USA

[5] Hosp Civils Lyon, Dept Dermatol, Pierre Benite, France

[6] Rochester Skin Lymphoma Med Grp, PLLC, Fairport, NY USA

[7] Washington Univ, Dept Med, Div Oncol, St Louis, MO USA

[8] CHU Rouen, Hop Charles Nicolle, Dept Dermatol, Rouen, France

[9] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[10] Univ Ziekenhuis Leuven, Dept Gen Med Oncol, Leuven, Belgium

[11] Charite Univ Med Berlin, Dept Dermatol Venerol & Allergol, Berlin, Germany

[12] Hosp Clin Barcelona, Dept Dermatol, Barcelona, Spain

[13] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[14] Univ Paris Cite, Dept Pathol, Hop St Louis, INSERM U976, Paris, France

[15] Univ Virginia, Dept Pathol, Sch Med, Charlottesville, VA USA

[16] Univ Paris Cite, Hop St Louis, AP HP, Hematol Lab,INSERM 1160, Paris, France

[17] Innate Pharma, Marseille, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7082

引用

页数：1

共 50 条

[41] Phase I Hypofractionation Trial of Relapsed/Refractory Lymphoma: Preliminary Results
Rajeev-Kumar, G.
McKeever, M. R.
Koshy, M.
McCall, A. R.
Arif, F.
Smith, S. M.
Kline, J.
Riedell, P.
Hasans, Y.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S67 - S68
[42] High Dose Cytarabine and Clofarabine (HiDAC→CLOF) in Relapsed or Refractory Acute Myeloid Leukemia, a Phase 2 Trial.
Powell, Bayard
D'Agostino, Ralph, Jr.
Levitan, Denise
Ellis, Leslie Renee
Lyerly, Susan
Skiles, Megan
Manuel, Megan
Harrelson, Robin
Kimbrough, Claire
Hurd, David Duane
BLOOD, 2008, 112 (11) : 676 - 676
[43] A phase II trial of Gleevec™ in patients with refractory/relapsed myeloma
Dispenzieri, A
Witzig, TE
Lacy, MQ
Geyer, SM
Kimlinger, T
Rajkumar, SV
Greipp, PR
Fonseca, R
Lust, JA
Zeldenrust, SR
Hayman, SR
Gertz, MA
BLOOD, 2004, 104 (11) : 665A - 665A
[44] A phase II trial of imatinib in patients with refractory/relapsed myeloma
Dispenzieri, A
Gertz, MA
Lacy, MQ
Geyer, SM
Greipp, PR
Rajkumar, SV
Kimlinger, T
Lust, JA
Fonseca, R
Allred, J
Witzig, TE
LEUKEMIA & LYMPHOMA, 2006, 47 (01) : 39 - 42
[45] Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: Results from a multicenter phase II trial
Levine, AM
Tulpule, A
Tessman, D
Kaplan, L
Giles, F
Luskey, BD
Scadden, DT
Northfelt, DW
Silverberg, I
Wernz, J
Espina, B
VonHoff, D
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 1094 - 1103
[46] Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial
Maruyama, Dai
Porcu, Pierluigi
Tobinai, Kensei
Allen, Pamela B.
Ishitsuka, Kenji
Tsukasaki, Kunihiro
Kusumoto, Shigeru
Narita, Tomoko
Foss, Francine
Yamauchi, Nobuhiko
Yuda, Junichiro
Morishima, Satoko
Imaizumi, Yoshitaka
Izutsu, Koji
Feldman, Tatyana
Kawamata, Toyotaka
Kakurai, Yasuyuki
Yamauchi, Hideyuki
Biserna, Noha
Inoue, Ai
Tachibana, Masaya
Hizukuri, Yoshiyuki
Horwitz, Steven
Jacobsen, Eric
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S523 - S524
[47] Subcutaneous Epcoritamab in Combination with R 2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial
Linton, Kim M.
Wahlin, Bjorn
Leepa, Sirpa
Morschhauser, Franck
Elliot, Brian
Liu, Tracy
Stirner, Mariana Cota
Abbas, Aqeel
Falchi, Lorenzo
BLOOD, 2021, 138
[48] Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Alexander M. Lesokhin
Michael H. Tomasson
Bertrand Arnulf
Nizar J. Bahlis
H. Miles Prince
Ruben Niesvizky
Paula Rodrίguez-Otero
Joaquin Martinez-Lopez
Guenther Koehne
Cyrille Touzeau
Yogesh Jethava
Hang Quach
Julien Depaus
Hisayuki Yokoyama
Afshin Eli Gabayan
Don A. Stevens
Ajay K. Nooka
Salomon Manier
Noopur Raje
Shinsuke Iida
Marc-Steffen Raab
Emma Searle
Eric Leip
Sharon T. Sullivan
Umberto Conte
Mohamed Elmeliegy
Akos Czibere
Andrea Viqueira
Mohamad Mohty
Nature Medicine, 2023, 29 : 2259 - 2267
[49] Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Lesokhin, Alexander H.
Tomasson, Michael
Arnulf, Bertrand J.
Bahlis, Nizar
Prince, H. Miles
Niesvizky, Ruben
Rodriguez-Otero, Paula
Martinez-Lopez, Joaquin
Koehne, Guenther
Touzeau, Cyrille
Jethava, Yogesh
Quach, Hang
Depaus, Julien
Yokoyama, Hisayuki
Gabayan, Afshin Eli A.
Stevens, Don K.
Nooka, Ajay
Manier, Salomon
Raje, Noopur
Iida, Shinsuke
Raab, Marc-Steffen
Searle, Emma
Leip, Eric T.
Sullivan, Sharon
Conte, Umberto
Elmeliegy, Mohamed
Czibere, Akos
Viqueira, Andrea
Mohty, Mohamad
NATURE MEDICINE, 2023, 29 (09) : 2259 - +
[50] Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib
Richardson, Paul
Wolf, Jeffrey
Jakubowiak, Andrzej
Zonder, Jeffrey
Lonial, Sagar
Irwin, David H.
Densmore, John
Krishnan, Amrita
Raje, Noopur
Bar, Michael H.
Allerton, Jeffrey P.
Schlossman, Robert
Ghobrial, Irene M.
Munshi, Nikhil C.
Martin, Thomas
Laubach, Jacob
Colson, Kathy
Dean, Sarah
Tocco, Deanna
Steinfield, Elizabeth
Kendall, Tara
O'Riley, Kimberly
Hideshima, Teru
Sportelli, Peter
Gardner, Lesa
Anderson, Kenneth C.
BLOOD, 2008, 112 (11) : 321 - 322

← 1 2 3 4 5 →